Quantcast
Channel: BioTuesdays » TSX-V:CTH
Browsing all 28 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

Cynapsus closes private placement

Cynapsus Therapeutics (TSX-V:CTH) has closed a brokered private placement of 3.4 million units at a price of 5 cents a unit to raise gross proceeds of $170,000 for working capital purposes. Each Unit...

View Article



Image may be NSFW.
Clik here to view.

Cynapsus drug one of top ten neurology projects

Cynapsus Therapeutics’ (TSX-V:CTH) APL-130277 for Parkinson’s disease was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee, including Dr. Harry Tracy,...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus files short-form prospectus

ynapsus Therapeutics (TSX-V:CTH) has filed a preliminary short-form prospectus with the securities regulatory authorities in British Columbia, Alberta and Ontario in connection with a best-effort...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus gets Notice of Allowance for oral Parkinson’s drug patent

Cynapsus Therapeutics (TSX-V:CTH) has received a notice of allowance from the U.S. Patent and Trademark Office for the patent application covering critical claims directed to thin film compositions...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus files short form prospectus

Cynapsus Therapeutics (TSX-V:CTH) has received a receipt for its final short form prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta...

View Article


Image may be NSFW.
Clik here to view.

Cynapsus closes $6-million offering

Cynapsus Therapeutics (TSX-V:CTH) has completed a short-form prospectus offering of units for gross proceeds of slightly more than$6-million. Michael J. Fox Concurrent with the closing of the offering,...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus continues prospectus offering

Cynapsus Therapeutics (TSX-V:CTH) is continuing its previously announced offering under a short-form prospectus. On March 1, the company completed a closing for gross proceeds of $6,008,000, achieving...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus closes second tranche of offering

Cynapsus Therapeutics (TSX-V:CTH) has completed a second closing of its short-form prospectus offering of units for gross proceeds of $1.3-million, following the first closing of $6-million on March 1,...

View Article


Image may be NSFW.
Clik here to view.

Cynapsus names Dexcel execs to its board

Tomer Gold, VP of R&D, of closely-held Dexcel Pharma, and Ilan Oren, VP of business development at Dexcel, have joined the board of Cynapsus Therapeutics (TSX-V:CTH). Dexcel recently acquired...

View Article


Image may be NSFW.
Clik here to view.

Zacks starts Cynapsus at buy

Zachs Research has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and price target of $1.25, calling the company an “undiscovered gem.” The stock was quoted at 40 cents...

View Article

Image may be NSFW.
Clik here to view.

Noble starts Cynapsus at buy

Noble Financial Capital Markets has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and 12-month price target of $1.75. The stock closed at 38 cents on Monday. Cynapsus is...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus to start trading on OTCQX International

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) common shares have been approved for trading in the U.S. on the OTCQX marketplace, with trading  to commence immediately under the symbol CYNAF. Trading...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus names Nan Hutchinson to board

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Nan Hutchinson to its board. Nan Hutchinson Over the past decade, Ms. Hutchinson was the SVP of marketing and sales for URL Pharma, helping...

View Article


Image may be NSFW.
Clik here to view.

Cynapsus PD data: couldn’t have wished for anything better

Anthony Giovinazzo “If I had asked for a gift, I couldn’t have wished for anything better,” says Anthony Giovinazzo, president and CEO of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH). He was...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus gains DTC approval

Common shares of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) have been made eligible for book-entry delivery and depository services of The Depository Trust Co. (DTC) to facilitate electronic...

View Article


Image may be NSFW.
Clik here to view.

Cynapsus finds 25-mg APL-130277 strip safe

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive interim data from its recently completed healthy volunteer pilot study of a single 25-milligram sublingual strip (APL-130277) dose...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus files for financing

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a preliminary short-form prospectus with securities agencies in the provinces of British Columbia, Alberta and Ontario for a best-efforts...

View Article


Image may be NSFW.
Clik here to view.

Cynapsus files final short-form prospectus for offering

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a final short-form prospectus in British Columbia, Alberta and Ontario to sell a minimum of 23,076,923 units and a maximum of 38,461,538 units...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus reports positive study data for APL-130277

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose...

View Article

Image may be NSFW.
Clik here to view.

Cynapsus sees no irritation in APL-130277 animal test

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) says there was no irritation observed when testing its APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters,...

View Article
Browsing all 28 articles
Browse latest View live




Latest Images